177 related articles for article (PubMed ID: 31611509)
1. Are there primary intraocular lymphomas that do not develop into central nervous system lymphomas?
Matsuo T; Tanaka T
J Clin Exp Hematop; 2019 Dec; 59(4):168-174. PubMed ID: 31611509
[TBL] [Abstract][Full Text] [Related]
2. Intraocular lymphoma: diagnostic approach and immunophenotypic findings in vitrectomy specimens.
Raparia K; Chang CC; Chévez-Barrios P
Arch Pathol Lab Med; 2009 Aug; 133(8):1233-7. PubMed ID: 19653716
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
4. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
5. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
6. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma.
Cho BJ; Yu HG
J Neurooncol; 2014 Dec; 120(3):523-9. PubMed ID: 25119002
[TBL] [Abstract][Full Text] [Related]
8. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome.
Coupland SE; Bechrakis NE; Anastassiou G; Foerster AM; Heiligenhaus A; Pleyer U; Hummel M; Stein H
Graefes Arch Clin Exp Ophthalmol; 2003 Oct; 241(10):860-70. PubMed ID: 14605902
[TBL] [Abstract][Full Text] [Related]
10. CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour.
Wenzel C; Dieckmann K; Fiebiger W; Mannhalter C; Chott A; Raderer M
Leuk Lymphoma; 2001 Aug; 42(4):823-9. PubMed ID: 11697516
[TBL] [Abstract][Full Text] [Related]
11. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
Chaput F; Amer R; Baglivo E; Touitou V; Kozyreff A; Bron D; Bodaghi B; LeHoang P; Bergstrom C; Grossniklaus HE; Chan CC; Pe'er J; Caspers LE
Ocul Immunol Inflamm; 2017 Oct; 25(5):639-648. PubMed ID: 27002464
[TBL] [Abstract][Full Text] [Related]
12. CD5-expressing B-cell lymphomas/leukemias: relatively high frequency of CD5+ B-cell lymphomas with an overall poor prognosis in Nagasaki Japan.
Kamihira S; Hirakata Y; Atogami S; Sohda H; Tsuruda K; Yamada Y; Tomonaga M
Leuk Lymphoma; 1996 Jun; 22(1-2):137-42. PubMed ID: 8724541
[TBL] [Abstract][Full Text] [Related]
13. CD19 immunostaining of a stored paraffin-embedded vitrectomy cell block of intraocular lymphoma contributing to chimera antigen receptor T-cell therapy.
Matsuo T; Tanaka T; Fujii N; Fujii K; Kondo E
J Clin Exp Hematop; 2022 Sep; 62(3):187-189. PubMed ID: 35732410
[No Abstract] [Full Text] [Related]
14. Cytopathologic findings of cell block materials from the vitreous: Diagnostic distinction between intraocular lymphoma and non-lymphomatous diseases.
Kanno-Okada H; Takakuwa E; Tagawa Y; Kase S; Hatanaka KC; Hatanaka Y; Namba K; Mitsuhashi T; Matsuno Y
Pathol Int; 2017 Jul; 67(7):342-349. PubMed ID: 28590047
[TBL] [Abstract][Full Text] [Related]
15. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA.
Bever GJ; Kim DJ; Afshar AR; Rubenstein JL; Damato BE
Retin Cases Brief Rep; 2020; 14(2):116-119. PubMed ID: 29210961
[TBL] [Abstract][Full Text] [Related]
16. Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous system lymphoma.
Akpek EK; Maca SM; Christen WG; Foster CS
Ophthalmology; 1999 Dec; 106(12):2291-5. PubMed ID: 10599659
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarker, phosphorylated T-LAK cell-originated protein kinase (p-TOPK) can predict outcome in primary central nervous system lymphoma.
Koh M; Hayakawa Y; Akai T; Hayashi T; Tomita T; Nagai S; Kuroda S
Neuropathology; 2018 Jun; 38(3):228-236. PubMed ID: 29575092
[TBL] [Abstract][Full Text] [Related]
18. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA; McCannel CA; Omuro AM; Ferreri AJ; Blay JY; Neuwelt EA; Siegal T; Batchelor T; Jahnke K; Shenkier TN; Hall AJ; Graus F; Herrlinger U; Schiff D; Raizer J; Rubenstein J; Laperriere N; Thiel E; Doolittle N; Iwamoto FM; Abrey LE
Neurology; 2008 Oct; 71(17):1355-60. PubMed ID: 18936428
[TBL] [Abstract][Full Text] [Related]
19. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.
Miller DC; Hochberg FH; Harris NL; Gruber ML; Louis DN; Cohen H
Cancer; 1994 Aug; 74(4):1383-97. PubMed ID: 8055462
[TBL] [Abstract][Full Text] [Related]
20. Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.
Abu Samra K; Oray M; Ebrahimiadib N; Lee S; Anesi S; Foster CS
Ocul Immunol Inflamm; 2018; 26(3):347-352. PubMed ID: 27438792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
